Life Sciences procurement leaders are navigating a new era of structural complexity. From advanced biologics delivery platforms that require earlier supplier engagement and capacity assurance, to the emergence of personalised and decentralised manufacturing models enabled by 3D printing, procurement is no longer simply supporting innovation - it is helping enable and scale it. These shifts demand new supplier strategies, revised qualification frameworks and a more forward-looking sourcing lens.
What You’ll Find Inside This Playbook
-
Strategic Move 1: Elevate Biologics Delivery to a Core Procurement Priority
Delivery platforms are becoming strategic constraints and competitive differentiators. Capacity assurance, dual sourcing and earlier supplier engagement will be critical.
-
Strategic Move 2: Prepare for the Shift from Batch to Bespoke Manufacturing
3D printing and personalised therapies are entering regulated environments, requiring procurement to adapt qualification models, supplier governance and category strategies.
-
Moves 3 and 4 focus on building regional resilience and embedding sustainability at the core of procurement strategy.
As geopolitical pressure and accelerating onshoring reshape global manufacturing footprints, procurement must move from price-led sourcing to risk-based regional alignment. At the same time, Scope 3 accountability and supplier decarbonisation are transforming sustainability from a reporting obligation into a strategic lever embedded in category governance and supplier selection.
Fill out the form on the right to download the 2026 Life Sciences Procurement Playbook and explore all four strategic moves in depth.